FNY Managed Accounts’s Aratana Therapeutics PETX Stock Holding History
Bought
Maintained
Sold
Other funds holding PETX
FNY Managed Accounts's PETX Position: Q1 2018 in Review
FNY Managed Accounts held its Aratana Therapeutics (PETX) position steady in Q1 2018 at 500 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #470.
FNY Managed Accounts first reported a position in PETX in Q1 2015 and has held it in 6 quarters since. The position peaked at $348K in Q2 2015. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.
- FNY Managed Accounts held 500 shares of Aratana Therapeutics worth $2K as of Q1 2018.
- FNY Managed Accounts left its Aratana Therapeutics share count unchanged in Q1 2018.
- Aratana Therapeutics made up ﹤0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #470 holding.
- FNY Managed Accounts first reported a position in Aratana Therapeutics in Q1 2015 and has held it in 6 quarters since.
- FNY Managed Accounts's Aratana Therapeutics position peaked at $348K in Q2 2015.
- 103 funds tracked by Wall St. Rank held Aratana Therapeutics as of Q1 2018.
Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.